Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

IBD

This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

J&J takes option on Theravance’s JAK drug in $1bn deal

J&J takes option on Theravance’s JAK drug in $1bn deal

TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients. Johnson &Johnson is paying $100m upfront for opt-in rights to a JAK inhibitor developed by Theravance, with another

Latest news

  • Takeda unveil final chapters of first graphic novel The Unbeatables Takeda unveil final chapters of first graphic novel The Unbeatables

    Chantel Wicks, IBD Unmasked patient panel member, said: “Only a person with IBD can understand what it is truly like. ... IBD Unmasked has shed light on the patient experience and given me the opportunity to have a positive impact on the IBD

  • Takeda and Marvel extend IBD cartoon initiative Takeda and Marvel extend IBD cartoon initiative

    Takeda and Marvel extend IBD cartoon initiative. Next chapter of IBD Unmasked released to celebrate World IBD Day. ... s disease and Luminaria, a nurse from Singapore that can soothe her IBD patients with her superhuman powers.

  • Takeda and Marvel launch IBD superhero squad Takeda and Marvel launch IBD superhero squad

    Takeda and Marvel launch IBD superhero squad. The comic book initiative aims to raise awareness of the gastrointestinal disease. ... The IBD Unmasked comic series seeks to raise awareness of the “ unsung heroes” who live with the disease on a daily

  • PMEA 2016 finalists announced PMEA 2016 finalists announced

    In the patient and customer-centric education and support programmes category, AstraZeneca's 'Life after heart attack' project and the British Society of Gastroenterology's 'IBD Registry Roadshow' are among those

  • Biologics set to revolutionise the gastrointestinal market Biologics set to revolutionise the gastrointestinal market

    biologics. Jennifer Goossens, associate analyst for GBI Research, said: “ Due to the high costs and adverse effects, biologic treatments are primarily used in patients with refractory inflammatory bowel disease (IBD), but ... Also contributing to the

More from news
Approximately 9 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc) plus

  • Deal Watch June 2016 Deal Watch June 2016

    IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.

  • Deal Watch October 2015 Deal Watch October 2015

    Janssen's partnership with Canadian biotech enGene, facilitated through J&J Innovation, brings gene therapies for inflammatory bowel disease (IBD) and includes an undisclosed upfront payment and equity investment, R&D ... Research collaboration, option,

  • Pharma deals in June 2015 Pharma deals in June 2015

    the treatment of inflammatory bowel disease (IBD). ... 130. Lycera Corporation/ Celgene Corporation. Orally bioavailable RORgamma agonists for ex vivo use lead programme, LYC-30937 (oral gut-directed ATPase modulator for IBD, p1).

  • Getting real about patient support Getting real about patient support

    opposed to a series of acute episodes (such as in asthma, COPD or IBD).

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

  • Pharma and NHS working together for patients - the IBD Registry Industry Working Group

    Pharma and NHS working together for patients - the IBD Registry Industry Working Group. ... Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ ve achieved in their first year, and whether or not it’ s been

  • Joined-up thinking on anaemia

    Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’ s quality of life, but it’ s often under-treated. ... The partners share resources and skills and the project is the first to use the IBD

  • IBD Registry appoints first CEO

    2018. The IBD Registry is familiar to many as the first UK-wide collection of anonymised adult and paediatric IBD data for prospective audit and research. ... Amanda Quincey, current Chair of the IBD Registry Board commented, “ the Board are delighted

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch expands oncology and IBD portfolios. This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new

  • Living with Crohn's disease: a patient perspective

    Overview of Inflammatory Bowel Disease (IBD) and Crohn’ s disease. Not many people know exactly what  Crohn’ s disease is or how it’ s caused. ... Crohn’ s disease is a form of Inflammatory Bowel Disease (IBD), which causes inflammation of the

More from PMHub
Approximately 5 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia